The Effect of Transcranial Direct Current Stimulation (tDCS) on Dyspnoea Perception, Pulmonary Function and Functional Level During COPD Exacerbation

NCT ID: NCT06944626

Last Updated: 2025-09-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-04-08

Study Completion Date

2025-09-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Chronic obstructive pulmonary disease (COPD) is a treatable disease characterized by irreversible and progressive airflow limitation, which is a cause of high morbidity and mortality. Dyspnea is an important component of COPD exacerbations that changes functional level and prognosis and limits the patient's quality of life and activities of daily living. Since COPD patients complain a lot of dyspnea associated with reduced exercise capacity and worsening lung function, there is a great need to develop effective physiologically based rehabilitation techniques to restore the dysfunctional respiratory motor system. Evidence supporting the importance of task-specific training based on neural plasticity also applies to pulmonary rehabilitation for COPD. Alterations in neuroplasticity and cortical excitability, tDCS is a promising technique for modulating brain activity. As a painless, easy-to-use and noninvasive technique, tDCS has shown efficacy in relieving pain, which shares the same neural substrates as dyspnea. Similarities have been established between the pathophysiology of dyspnea and pain. Close or even overlapping activation zones of brain structures involved in the integration of pain and dyspnea have been emphasized. Therefore, it is hypothesized that tDCS stimulation of areas where one or more of these cerebral structures are activated in pain may also have an effect on dyspnea. In light of this information, researchers believe that relieving dyspnea with tDCS will have an impact on the prognosis of patients during COPD exacerbations. In this context, researchers will evaluate the effects of tDCS on dyspnea perception, lung function, and functional level in patients with COPD exacerbation. When the literature was reviewed, no study on the use of tDCS in COPD patients was found. The use of tDCS as a non-invasive and easy-to-use effective treatment method with neuro-modulation to combat dyspnea and functional level in COPD patients constitutes the originality of the study.

Forty patients who were hospitalized in the Chest Diseases Service due to COPD exacerbation and met the inclusion criteria will be included in the study. The evaluation parameters included symptom assessment, breathlessness perception questionnaire, COPD assessment test, peripheral muscle strength assessment, grip strength assessment, pulmonary function test, Montreal cognitive assessment test, London chest activities of daily living scale, timed up and go test, hospital anxiety and depression scale, respiratory muscle strength, fNIRS and capnography. Assessments will take place before and after treatment. Sham (n:20) group will receive conventional physiotherapy and sham tDCS, while the Study (n:20) group will receive tDCS and conventional physiotherapy. For anodal tDCS, the anode electrode will be placed over the left primary motor cortex and the cathode will be placed over the right supraorbital region. For the study group, tDCS application will be applied with a current of 2 mA for 30 minutes on 3 consecutive days. In the sham group, tDCS application will be increased to 2 mA for the first 30 seconds and then decreased to 0 mA within 30 seconds after receiving current for 15 seconds. The electrodes will remain on the patient's head for the rest of the time (30 minutes in total).

In conclusion, the effects of tDCS on dyspnea perception, pulmonary function and functional level in COPD exacerbation period patients will be investigated. At the same time, the advantages of tDCS administration in COPD patients will be evaluated by examining its effects on cerebrovascular responses, tissue oxygenation, muscle strength, cognitive level, activity of daily living, anxiety and depression. It will provide different perspectives to clinicians and researchers who will create evaluation, treatment and study plans for COPD exacerbation period patients with limited treatment options and will be a guide for new research.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COPD Dyspnea tDCS

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Study Gruop

Conventional physiotherapy + tDCS

Group Type EXPERIMENTAL

tDCS

Intervention Type DEVICE

tDCS will be applied to the dorsalateral prefrontal cortex with a current of 2 mA for 30 minutes on 3 consecutive days.

Conventional physiotherapy

Intervention Type OTHER

Within the scope of conventional physiotherapy, respiratory control training, diaphragmatic breathing exercise, puckered lip breathing, relaxation exercises will be started 10 minutes after the start of tDCS or sham tDCS application.

While tDCS or sham tDCS application continues, 10 repetitions will be performed in order and with time for rest between exercises.

Sham group

Conventional physiotherapy + sham tDCS

Group Type SHAM_COMPARATOR

Sham tDCS

Intervention Type DEVICE

The tDCS application will be increased to 2 mA for the first 30 seconds and will be reduced to 0 mA within 30 seconds after receiving current for 15 seconds. The electrodes will remain on the patient's head for the rest of the time (30 min in total).

Conventional physiotherapy

Intervention Type OTHER

Within the scope of conventional physiotherapy, respiratory control training, diaphragmatic breathing exercise, puckered lip breathing, relaxation exercises will be started 10 minutes after the start of tDCS or sham tDCS application.

While tDCS or sham tDCS application continues, 10 repetitions will be performed in order and with time for rest between exercises.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

tDCS

tDCS will be applied to the dorsalateral prefrontal cortex with a current of 2 mA for 30 minutes on 3 consecutive days.

Intervention Type DEVICE

Sham tDCS

The tDCS application will be increased to 2 mA for the first 30 seconds and will be reduced to 0 mA within 30 seconds after receiving current for 15 seconds. The electrodes will remain on the patient's head for the rest of the time (30 min in total).

Intervention Type DEVICE

Conventional physiotherapy

Within the scope of conventional physiotherapy, respiratory control training, diaphragmatic breathing exercise, puckered lip breathing, relaxation exercises will be started 10 minutes after the start of tDCS or sham tDCS application.

While tDCS or sham tDCS application continues, 10 repetitions will be performed in order and with time for rest between exercises.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosed with COPD and followed up for at least 6 months
* Hospitalised due to an exacerbation
* Have not taken any medication affecting the nervous system in the last 6 months
* Co-operative
* Have the ability to participate in working procedures
* Over 18 years of age,
* The specialist physician finds it suitable for physiotherapy applications,
* Volunteers who want to participate in the study

Exclusion Criteria

* Having comorbidities other than COPD, such as bronchiectasis, lung cancer or asthma
* Surgery in the last 6 months (volume reduction surgery, etc.)
* Neuromuscular disease
* Pulmonary embolism or pulmonary oedema
* Presence of cranial, cardiac, spinal cord, intra-aural metal implants
* Epilepsy
* Patients on invasive mechanical ventilation
* Patient with cardiac pace maker
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Okan University

OTHER

Sponsor Role lead

Istinye University

OTHER

Sponsor Role collaborator

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Emine Atıcı

Assoc. Prof Dr

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

İstinye Üniversitesi

Istanbul, Zeytinburnu, Turkey (Türkiye)

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Turkey (Türkiye)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

11/2024.K-73

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

The Effect of Face Hand Fan Application on Dyspnea
NCT06265831 ACTIVE_NOT_RECRUITING NA